ADC Therapeutics SA at JPMorgan Healthcare Conference Transcript
Good morning, everyone. My name is [Mary Lou], and I am one of the associates on the Healthcare Investment Banking team at J.P. Morgan. It is my pleasure to introduce our next presentation from ADC Therapeutics. I am joined by the company CEO, Ameet Mallik, who will give a presentation on the business followed by a Q&A session. Thank you very much for being here. And with that, I will turn it over to you.
Thank you very much. It is a pleasure to be here with all of you today. And I am very happy to introduce our company, ADC Therapeutics. So overall, we're in the ADC stage. We have an approved product in ZYNLONTA that we're currently working to expand in combination in earlier lines of DLBCL and in indolent lymphomas.
Over the course of 2025, we made significant accomplishments, most notably progress with all of our key trials. We're able to again demonstrate key data which we believe is de-risking the portfolio of trials for ZYNLONTA but also to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
